Understanding FDA Status: Approved vs. Compounding-Eligible vs. Research-Only

Three Tiers, Three Very Different Realities

If you’ve browsed the National Peptide Registry, you’ve noticed that every peptide profile carries a regulatory status label. But what do those labels actually mean in practice? The distinction between “FDA-Approved,” “Compounding-Eligible,” and “Research-Only” isn’t just bureaucratic fine print — it has real implications for safety, access, legality, and cost.

Let’s break it down.

Tier 1: FDA-Approved

This is the gold standard. An FDA-approved peptide has gone through the full regulatory gauntlet: preclinical studies, Phase I/II/III clinical trials involving thousands of patients, manufacturing inspections, and ongoing post-market surveillance.

Examples you’ll find in our registry:

• Semaglutide — marketed as Ozempic (diabetes) and Wegovy (weight management) by Novo Nordisk. Backed by extensive clinical trial data demonstrating significant effects on HbA1c reduction and weight loss.
• Liraglutide — marketed as Victoza and Saxenda. An earlier GLP-1 receptor agonist with a strong evidence base.
• Tirzepatide — marketed as Mounjaro and Zepbound by Eli Lilly. A dual GIP/GLP-1 receptor agonist that has shown remarkable efficacy in clinical trials.

When a peptide is FDA-approved, it means a pharmaceutical company has invested hundreds of millions of dollars to prove that it works and that its benefits outweigh its risks for a specific indication. It’s manufactured under strict Good Manufacturing Practice (GMP) standards and prescribed by licensed physicians.

What this means for you: These are the most studied, most regulated, and generally safest option. You get them through a standard prescription from your doctor, filled at a licensed pharmacy.

Tier 2: Compounding-Eligible

This is where things get more nuanced. Compounding pharmacies are licensed facilities that can prepare custom medications — including peptides — under a physician’s prescription. Historically, compounding has served an important role: creating formulations that aren’t commercially available, adjusting dosages, or removing allergens.

For peptides, compounding became especially popular when demand for GLP-1 drugs like semaglutide outstripped supply. Compounding pharmacies stepped in to fill the gap, producing their own versions at lower prices.

However, the regulatory landscape here is shifting rapidly:

• The FDA has been increasingly scrutinizing compounded peptides, particularly GLP-1 agonists, as drug shortages have resolved.
• Compounded peptides do not go through the same clinical trial process as FDA-approved drugs. Their safety and efficacy are not independently verified by the FDA.
• Quality can vary between compounding pharmacies. Not all facilities maintain the same standards.

What this means for you: Compounded peptides are legal when prescribed by a doctor and prepared by a licensed compounding pharmacy. However, they carry more uncertainty than FDA-approved versions. Always verify that your compounding pharmacy is accredited (look for PCAB accreditation) and that your prescribing physician is actively monitoring your treatment.

Tier 3: Research-Only

This is the category that generates the most confusion — and the most risk. “Research-only” means exactly what it says: these peptides are sold for laboratory research purposes and are not approved for human therapeutic use by the FDA.

Many of the most talked-about peptides fall into this category:

• BPC-157 — widely discussed for tissue repair and gut healing. Animal studies are promising, but there are no completed human clinical trials establishing safety or efficacy.
• Selank and Semax — approved as medications in Russia but classified as research compounds in the United States.
• TB-500 — studied for wound healing properties but lacking the clinical evidence required for FDA approval.
• LL-37 — an antimicrobial peptide with interesting immunological properties, still firmly in the research phase.

It’s also worth noting that several research-only peptides appear on the World Anti-Doping Agency (WADA) prohibited list. Athletes subject to drug testing should be especially cautious — even peptides marketed as “supplements” can trigger positive tests and result in sanctions.

What this means for you: Research-only peptides exist in a legal and medical gray zone. They’re not illegal to possess in most jurisdictions, but they’re not approved for you to inject, inhale, or otherwise use therapeutically. If you choose to use them, you’re doing so without the safety net of FDA oversight, standardized manufacturing, or clinical trial evidence. We don’t recommend or discourage their use — we simply present the data and let you make an informed decision.

Why This Matters

The regulatory status of a peptide isn’t just a label — it’s a proxy for how much we actually know about it. FDA-approved peptides have been tested in thousands of people. Research-only peptides may have been tested in a few dozen rats.

That doesn’t mean research-only peptides are dangerous. It doesn’t mean they don’t work. It means we don’t have enough evidence yet to say with confidence either way. And that uncertainty is exactly what the NPR exists to make visible.

Every peptide in our registry is clearly labeled with its current regulatory status. Explore the registry to see for yourself.